Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Debt-to-Asset : 0.26 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Asset?

Shenzhen Hepalink Pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$3,416 Mil. Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$1,956 Mil. Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was HK$20,504 Mil. Shenzhen Hepalink Pharmaceutical Group Co's debt to asset for the quarter that ended in Mar. 2024 was 0.26.

Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Asset Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Asset Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.42

0.30

0.31

0.29

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.31	0.30	0.29	0.29	0.26

Competitive Comparison of Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset falls into.

Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4005.832	+	2078.659)	/	21004.29
	=	0.29

Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3416.035	+	1955.66)	/	20503.909
	=	0.26

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Shenzhen Hepalink Pharmaceutical Group Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Debt-to-Asset

Traded in Other Exchanges

002399:China

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Executives

Orbimed Capital Llc	2102 Investment manager
Morgan Stanley & Co. International Plc	2105 Underwriter
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Avict Global Holdings Limited	2101 Beneficial owner
Worldwide Healthcare Trust Plc	2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Headlines

No Headlines